AMEGA Biotech

Executive Summary

AMEGA Biotech is an Argentine company specializing in the development and production of radiopharmaceuticals for both diagnostic imaging and therapeutic applications in nuclear medicine. Founded in 2005 and currently in the commercial stage, the company has established itself as a key player in the Latin American nuclear medicine market. With a workforce of 50-200 employees, AMEGA leverages its expertise in radioisotope technology to address unmet needs in oncology and diagnostics. The company's product portfolio spans SPECT and PET imaging agents, as well as targeted radionuclide therapies, positioning it to capitalize on the growing demand for theranostics. As a private entity, AMEGA is well-positioned to expand its footprint beyond Argentina into broader Latin American and potentially global markets, driven by increasing adoption of nuclear medicine procedures and favorable regulatory pathways for radiopharmaceuticals.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval for therapeutic radiopharmaceutical candidate60% success
• TBDStrategic partnership or distribution agreement with a global pharma50% success
• Q4 2026Expansion into new Latin American markets (e.g., Brazil, Mexico)70% success